Oxford Nanopore has shipped 200 MinION sequencers and consumables to China to help with surveillance of the coronavirus outbreak.
The shipment follows extensive collaboration with public health professionals in China and adds to a large number of MinION devices already in the country.
The company, which has its headquarters on Oxford Science Park, is working with more than 100 public health laboratories in China, plus a number of Chinese microbiology laboratories and global public health scientists.
“We hope that the nanopore vision of enabling anyone to access biological information anywhere, can have a positive impact, and are immensely grateful for the community support as we work to rapidly optimise for this outbreak.”
The MinION sequencer weighs less than 100g and is run with a laptop or special accessory, the MinIT, to perform data analysis. It streams sequence data in real time, allowing for rapid sequencing. It has previously performed sequencing in rural or remote settings, such as during the Ebola and Zika virus outbreaks.
Rapid sequencing of the coronavirus has been an essential tool in helping scientists to understand the outbreak. Sequence information is combined with location and time data, to give valuable insight into how the virus is spreading and whether it is changing.
Oxford Nanopore Technologies also has offices in Shanghai, Tokyo, Singapore, New York, San Francisco and Cambridge in Massachusetts.
Oxford biotech company e-therapeutics is offering its powerful network-biology-and AI-based drug discovery platform to help tackle the Covid-19 pandemic.
Using its proprietary tech, a biotech company has discovered antibodies leading to the development of drug discovery programmes in kidney disease and cancer.
Researchers in Oxford and Zurich have used artificial intelligence (AI) and computer visualisation technology to detect changes in colon cancer cells that could be connected to the ‘expression’ of some smell-sensing genes.